Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck astraZeneca (Lynparza & Koselugo Oncology Alliance) — Cost of sales profit-sharing & manufacturing ($M) ($M)
Form 10-Q / 10-K Note 3/4 Collaborative Arrangements
Latest, Q2 2026
84
Period ended Jun 30, 2026
Change on a year earlier
-2.3%
86 in Q2 2025
History
30 quarters
Since Q1 2019
Sources
25
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Cost of sales profit-sharing & manufacturing ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 84 | -2.3% | Form 10-Q (filed 2026-08-07) ↗ |
| Q1 2026 | Mar 31, 2026 | 84 | +1.2% | Form 10-Q (filed 2026-05-04) ↗ |
| Q4 2025 | Dec 31, 2025 | 85 | -36.1% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2025 | Sep 30, 2025 | 84 | +2.4% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 86 | +4.9% | Form 10-Q (filed 2026-08-07) ↗ |
| Q1 2025 | Mar 31, 2025 | 83 | +1.2% | Form 10-Q (filed 2026-05-04) ↗ |
| Q4 2024 | Dec 31, 2024 | 133 | +64.2% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2024 | Sep 30, 2024 | 82 | 0.0% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2024 | Jun 30, 2024 | 82 | +5.1% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 82 | +17.1% | Form 10-Q (filed 2025-05-02) ↗ |
| Q4 2023 | Dec 31, 2023 | 81 | +20.9% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2023 | Sep 30, 2023 | 82 | +28.1% | Form 10-Q (filed 2024-11-06) ↗ |
| Q2 2023 | Jun 30, 2023 | 78 | +25.8% | Form 10-Q (filed 2024-08-05) ↗ |
| Q1 2023 | Mar 31, 2023 | 70 | -76.6% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2022 | Dec 31, 2022 | 67 | +59.5% | Form 10-K (filed 2025-02-25) ↗ |
| Q3 2022 | Sep 30, 2022 | 64 | +52.4% | Form 10-Q (filed 2023-11-03) ↗ |
| Q2 2022 | Jun 30, 2022 | 62 | +47.6% | Form 10-Q (filed 2023-08-07) ↗ |
| Q1 2022 | Mar 31, 2022 | 299 | +611.9% | Form 10-Q (filed 2023-05-05) ↗ |
| Q4 2021 | Dec 31, 2021 | 42 | 0.0% | Form 10-K (filed 2024-02-26) ↗ |
| Q3 2021 | Sep 30, 2021 | 42 | +2.4% | Form 10-Q (filed 2022-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 42 | -69.3% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 42 | +50.0% | Form 10-Q (filed 2022-05-05) ↗ |
| Q4 2020 | Dec 31, 2020 | 42 | +50.0% | Form 10-K (filed 2023-02-24) ↗ |
| Q3 2020 | Sep 30, 2020 | 41 | +46.4% | Form 10-Q (filed 2021-11-05) ↗ |
| Q2 2020 | Jun 30, 2020 | 137 | +87.7% | Form 10-Q (filed 2021-08-09) ↗ |
| Q1 2020 | Mar 31, 2020 | 28 | +47.4% | Form 10-Q (filed 2021-05-05) ↗ |
| Q4 2019 | Dec 31, 2019 | 28 | – | Form 10-K (filed 2022-02-25) ↗ |
| Q3 2019 | Sep 30, 2019 | 28 | – | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 73 | – | Form 10-Q (filed 2020-08-05) ↗ |
| Q1 2019 | Mar 31, 2019 | 19 | – | Form 10-Q (filed 2020-05-06) ↗ |
Cite this data
StockData. (2026). Merck AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Cost of sales profit-sharing & manufacturing ($M) ($M), quarterly Q1 2019–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/collab_astrazeneca_cos
See every metric in the Merck KPI table. Data updated Oct 26, 2026.